IMRN | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

-3.37%

1 Month

-3.37%

3 Months

-11.79%

6 Months

-22.17%

1 Year

-37.57%

2 Year

-10.88%

Key data

Stock price

$1.72

P/E Ratio

0.00

DAY RANGE

$1.70 - $1.85

EPS

N/A

52 WEEK RANGE

$1.66 - $2.89

52 WEEK CHANGE

-$42.47

MARKET CAP

15.219 M

YIELD

N/A

SHARES OUTSTANDING

5.700 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

-0.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$12,473

AVERAGE 30 VOLUME

$15,682

Company detail

CEO: Steven Lydeamore
Region: US
Website: immuron.com.au
Employees: 5
IPO year: 2017

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.

IMRN - Immuron Ltd